FATE News and Press, Fate Therapeutics Inc. From 05/03/23

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CAR NK Cell Program Accruing Patients in Multi-dose E...

2023-05-02 03:11:45 ET Summary Fortune is slowly turning in favor of Cathie Wood and her investment management firm as the rapid decline of her ETFs and their underlying assets has perhaps finally bottomed. Front-running tech stocks have delivered unexpectedly good earnings in def...

2023-05-01 12:40:00 ET Summary The month of April had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived ...

2023-03-28 17:27:17 ET Gainers: Arcturus Therapeutics ( ARCT ) +15% . lululemon athletica ( LULU ) +11% . Fate Therapeutics ( FATE ) +5% . Kezar Life Sciences ( KZR ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Losers: ...

2023-03-26 06:37:55 ET Summary NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down. It could be a result of Fate's recent debacle, or because, as Oppenheimer says, the ship has already sailed. Nkarta ( NKTX )...

2023-03-24 07:13:27 ET Summary Fate Therapeutics' recent Janssen debacle has brought out comparisons with Geron. However, let's not forget that Geron has never gone back to pre-2019 prices. Fate investors would do well when they rethink their strategy. Fate Therapeut...

2023-03-23 08:56:52 ET Popular biotech exchange traded fund SPDR S&P Biotech ETF ( NYSEARCA: XBI ) dropped more than 3% on Wednesday. As a result, the ETF reached a new 8-month low. XBI touched $73.06 a share on Wednesday which marked its lowest level dating back to ...

New York, New York--(Newsfile Corp. - March 16, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit. The lawsuit on behalf of Fate investors has been commenced in the the United States Dis...

San Diego, California--(Newsfile Corp. - March 7, 2023) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE). Investors who purchased Fate Therapeutics, Inc. (NASDAQ: FATE) shares prior to April 2, 2020,...